GLPG0259 in Methotrexate-refractory Rheumatoid Arthritis

Rheumatoid Arthritis Clinical Trial

Official title:

Randomized, Double-Blind, Placebo-Controlled, Multicenter, Exploratory Phase II Study to Compare Three Dose Regimens of GLPG0259 vs Placebo, in Combination With Methotrexate, Administered for 12 Weeks to Subjects With Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01211249
• Other study ID #: GLPG0259-CL-201
• Secondary ID: 2009-015898-12
• Status: Completed
• Phase: Phase 2
• First received: September 28, 2010
• Last updated: April 22, 2011
• Start date: October 2010
• Est. completion date: April 2011

Study information

• Verified date: April 2011
• Source: Galapagos NV
• Contact: n/a
• Is FDA regulated: No
• Health authority: Belgium: Federal Agency for Medicinal Products and Health ProductsRussia: Ministry of Health of the Russian FederationUkraine: Ministry of HealthNetherlands: The Central Committee on Research Involving Human Subjects (CCMO)Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products
• Study type: Interventional

Clinical Trial Summary

Part A: 30 patients suffering from active rheumatoid arthritis despite continued treatment with methotrexate will receive once daily two capsules containing either GLPG0259 (25 mg/capsule) or matching placebo, for 12 weeks. In the course of the study the patients will be examined for severity of disease, as well as for any adverse effects that may occur. If needed, dosing may be split to one capsule twice daily, or reduced to one capsule of 25 mg.

Part B: If results of Part A suggest test medication to have a therapeutic advantage over placebo and to be well-tolerated, more patients will be recruited for Part B, where various dosages will be assessed. These dosages will be established based on results from Part A.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: April 2011
• Est. primary completion date: April 2011
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Must have active RA (=5 tender or painful joints on motion and =5 joints swollen AND a C-reactive protein (CRP) concentration =1.5 mg/dL).

• Must have been on methotrexate for =6 months at a stable dose of 7.5-25 mg/week for =12 weeks, to be continued throughout study;

• If on oral steroids, these should be at a dose =10 mg/day of prednisone eq and stable for =4 weeks prior to screening;

• If on NSAIDs, these must be at a stable dose for =2 weeks prior to screening;

• Women must have negative pregnancy test unless surgically sterile or post-menopausal for =1 year;

• Women of childbearing potential must use a medically acceptable means of birth control and agree to continue its use during the study and for =12 weeks after the last dose of study drug.

• Informed consent

Exclusion Criteria:

• Must not have received treatment with DMARDs, other than background methotrexate;

• Must not be receiving or have received RA treatment with a biological agent, except if administered in a clinical study =six months prior to screening (12 months for rituximab or other B cell depleting agents);

• Must not have received any treatment with a cytotoxic agent, other than methotrexate, before screening (e.g. chlorambucil, cyclophosphamide, nitrogen mustard, or other alkylating agents);

• Must not have received intra-articular or parenteral corticosteroid injection within four weeks prior to screening;

• Must not regularly be using aspirin or any other anti-coagulant medication;

• Must not have a known hypersensitivity to study drug ingredients or a significant allergic reaction to any drug as determined by the Investigator, such as anaphylaxis, requiring hospitalization;

• Must not have positive serology for human immunodeficiency virus (HIV)1 or 2 or hepatitis B or C, or any history of HIV or hepatitis from any cause with the exception of hepatitis A;

• Must not have a history of any inflammatory rheumatological disorders other than RA;

• Must not have undergone (or planned) surgical treatments for RA;

• Must not have symptoms of clinically significant illness other than RA (including but not limited to cardiopulmonary, renal, metabolic, hematologic, or psychiatric disorders) within three months prior to screening;

• Must not have a history of active infections requiring intravenous antibiotics within the past four weeks;

• Must not have a history of malignancy within the past five years (except for basal cell carcinoma of the skin or carcinoma in situ of the cervix that has been treated with no evidence of recurrence);

• Must not have a history of tuberculosis (TB) infection as determined by a positive diagnostic TB test result (defined as a positive QuantiFERON TB Gold test), AND a recent chest radiograph (both posterior-anterior and lateral views), read by a qualified radiologist, with evidence of current active TB or old inactive TB.

• Must not have been administered a live vaccine within four weeks prior to screening;

• Must not have participated in any investigational drug/device clinical study within four weeks prior to screening, in biological agents clinical studies within six months prior to screening, and B cell-depleting agent clinical studies within 12 months prior to screening;

• Must not have a history within the previous two years or current evidence of drug or alcohol abuse;

• Must not have any condition or circumstances which in the opinion of the Investigator may make a subject unlikely or unable to complete the study or comply with study procedures and requirements, or may pose a risk to the patient's safety.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Arthritis
• Arthritis, Rheumatoid
• Rheumatoid Arthritis

Intervention

Drug:
• GLPG0259 oral capsule
Two capsules, each containing 25 mg of GLPG0259 (i.e. 50 mg/day), to be given once daily; in case of adverse events the dose may be split over two administrations, or reduced to 25 mg/day (one single capsule)
• Placebo
Placebo capsules; two capsules to be taken in the morning, in case of adverse events the dose may be split over two administrations, or reduced to one single capsule
• GLPG0259 (Part B)
Capsule, dosage to be established based on results of Part A
• Placebo (Part B)
Capsules, dosage to be established after Part A, and matching GLPG0259 (Part B)

Locations

Country	Name	City	State
Belgium	Cliniques Universitaires Saint-Luc	Brussels
Belgium	KU Leuven	Leuven
Belgium	AZ Alma	Sijsele-Damme
Netherlands	UMC Leiden	Leiden
Poland	Specjalistyczne Centrum Medyczne NZOZ NOWOMED	Kraków
Poland	"Linea Corporis" - Chirurgia Plastyczna Sp. z o.o.	Warszawa
Poland	Mokotowskie Centrum Osteoporozy S.C.	Warszawa
Poland	Akademia Medyczna im. Piastów Slaskich we Wroclawiu Katedra i Klinika Reumatologii i Chorób Wewnetrznych UM we Wroclawiu	Wroclaw
Poland	Synexus SCM Sp. z o.o.	Wroclaw
Russian Federation	Institution Russian Academy of Medical Sciences Scientific Research Institution of Rheumatology RAMN	Moscow
Russian Federation	Saint-Petersburg State Healthcare Institution "City Hospital #26"	Moscow
Russian Federation	State Educational Institution of Higher Professional Education "Moscow State Medico-Stomatological University of Roszdrav" at the State Healthcare Institution of city Moscow "City Clinical Ordena Trudovogo Krasnogo Znameny hospital #23 n.a. "M	Moscow
Russian Federation	State Educational Institution of Higher Professional Education "Moscow State Medico-Stomatological University of Roszdrav" State Healthcare Institution of City Moscow "City Clinical Ordena Trudovogo Krasnogo Znameny Hospital #23 n.a. "Medsantrud"	Moscow
Russian Federation	State Educational Institution of Higher Professional Education "Russian State Medical University of Roszdrav" State Healthcare Institution of City Moscow "City Clinical Hospital #15 n.a. O.M. Filatov"	Moscow
Russian Federation	State Healthcare Institution of City Moscow "City Clinical Hospital #1 n.a. Pirogov"	Moscow
Russian Federation	State Healthcare Institution of City Moscow "City Clinical Hospital #4"	Moscow
Russian Federation	State Healthcare Institution of City Moscow "City Clinical Hospital #7"	Moscow
Russian Federation	State Healthcare Institution of city Moscow "City Clinical Ordena Trudovogo Krasnogo Znameny Hospital #23 n.a. "Medsantrud"	Moscow
Russian Federation	Institution of Russian Academy of Sciences Saint-Petersburg Clinical Hospital RAN	St Petersburg
Russian Federation	Saint-Petersburg State Healthcare Institution "City Pokrovskaya Hospital"	St Petersburg
Russian Federation	Saint-Petersburg State Healthcare Institution "City Mariinskiy Hospital"	St-Petersburg
Russian Federation	State Educational Institution of Higher Professional Education "Saint-Petersburg State Pediatric Medical Academy of Roszdrav"	St. Petersburg
Ukraine	Chernivtsi Regional Clinical Hospital	Chernivtsi
Ukraine	Donetsk City Hospital No5	Donetsk
Ukraine	Kharkiv City Clinical Hospital No.27	Kharkiv
Ukraine	Kharkiv City Clinical Hospital No.8	Kharkiv
Ukraine	Central Pool-type Clinical Hospital MoH of Ukraine	Kyiv
Ukraine	Institute of Gerontology AMS of Ukraine	Kyiv
Ukraine	Kyiv City Clinical Hospital No.3	Kyiv
Ukraine	University Clinic, Crimean Medical University	Simferopol
Ukraine	Vinnytsia Regional Hospital	Vinnytsia
Ukraine	Zaporizhzhia Regional Hospital	Zaporizhzhya

Sponsors (1)

Lead Sponsor	Collaborator
Galapagos NV

Countries where clinical trial is conducted

Belgium,  Netherlands,  Poland,  Russian Federation,  Ukraine, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Efficacy	The primary efficacy endpoint will be the number and percentage of subjects in each GLPG0259 dose group and placebo group achieving an American College of Rheumatology (ACR)20 (ACR20 response rate) at Week 12.	12 weeks	No
Secondary	Efficacy	ACR20, ACR50, ACR75 and DAS28 (and components) at weeks 1, 2, 4, 8 and 12;	intermediate timepoints for 12 weeks	No
Secondary	Safety	At each return visit, patients will be asked about adverse events, and undergo examination of heart (ECG) and bloodpressure; blood- and urine-samples will be collected to monitor organ functions.	12 weeks	No
Secondary	Pharmacokinetics	On several timepoints throughout the study bloodsamples will be taken from the patient to establish the amount of the study medication in the blood, and to determine how long it stays in the blood.	12 weeks	No